$IART

INTEGRA LIFESCIENCES HOLDINGS CORP

Integra LifeSciences is a medical technology company that manufactures and sells products for healthcare professionals and providers worldwide. Its two segments are Codman Specialty Surgical, which supplies technologies and instruments for neurosurgery, neurocritical care, ear, nose and throat surgery, and other surgical procedures, and Tissue Technologies, which focuses on wound reconstruction and care and private label products. Codman Specialty Surgical products include intracranial pressure monitors, hydrocephalus management devices, dural grafts and sealants, surgical instruments, and ENT systems. Tissue Technologies offers regenerative tissue products for acute and chronic wounds, tissue repair, and surgery, as well as materials and product development and manufacturing services for medical technology companies that sell under their own labels. Integra sells through direct representatives and independent distributors to hospitals, health networks, clinicians, surgery centers, and other healthcare providers. It is headquartered in Princeton, New Jersey.

No enriched coverage for $IART in the last 7 days.

No SEC Form 4 filings for $IART in the last 30 days.

See all $IART insider activity →
Med

Integra's Q3 Beat Overshadowed by Rising Debt Costs, BTIG Says

Integra LifeSciences reported Q3 2026 revenue of $411.2M, up 2.3%, with GAAP EPS of $0.19 and adjusted EPS of $0.59. The company refinanced $2.1B in debt, increasing interest costs. BTIG maintains a Neutral rating, citing operational challenges and elevated leverage.

IART Maintained by Citigroup -- Price Target Lowered to $14.00

Citigroup maintained a Neutral rating on Integra Lifesciences (IART) but lowered its price target from $15.00 to $14.00. GuruFocus values IART at $20.43, suggesting a 40.6% undervaluation. The company has a GF Score of 69/100, indicating fair performance. IART operates in the medical devices sector and faces challenges in growth and financial strength.

IART sentiment & insider activity

Recent IART coverage spans earnings, financial news and corporate actions.

What's driving IART

AlphAI scores every news story that mentions IART with an AI model for sentiment and relevance, and aggregates insider trades from INTEGRA LIFESCIENCES HOLDINGS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IART

Score

IART Maintained by Citigroup -- Price Target Lowered to $14.00

Citigroup maintained a Neutral rating on Integra Lifesciences (IART) but lowered its price target from $15.00 to $14.00. GuruFocus values IART at $20.43, suggesting a 40.6% undervaluation. The company has a GF Score of 69/100, indicating fair performance. IART operates in the medical devices sector and faces challenges in growth and financial strength.

$IARTHighAI 8/10Earnings

Integra LifeSciences Reports Third Quarter 2026 Financial Results

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an SEC Form 8-K — Results of Operations and Financial Condition. News Release Integra LifeSciences Reports Third Quarter 2026 Financial Results PRINCETON, N.J., October 21, 2026 - Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending

$IARTHighDebt financing· $450M

INTEGRA LIFESCIENCES HOLDINGS CORP (IART): Entry into a Material Definitive Agreement

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Integra Announces Completion of Refinancing Transactions PRINCETON, N.J., Oct 19, 2026 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it has closed a private offering of $450.0 million aggregate principal amount of 9.5

Related tickers